Pulmonary valve stenosis is a condition characterized by obstruction to blood flow from the right ventricle to the pulmonary artery. This obstruction is caused by narrowing (stenosis) at one or more points from the right ventricle to the pulmonary artery. The most common form of pulmonary stenosis is obstruction at the valve itself, referred to as pulmonary valvar stenosis.
Pulmonary valve stenosis signs and symptoms vary, depending on the extent of the obstruction. People with mild pulmonary stenosis usually don't have symptoms. Pulmonary valve stenosis signs and symptoms may include Heart murmur - an abnormal whooshing sound heard using a stethoscope, caused by turbulent blood flow, Shortness of breath, especially during exertion, Chest pain, Loss of consciousness (fainting), Fatigue.
In Sweden the statistical analysis on pulmonary valve stenosis gave the result as the algorithm identified 928 children with hemodynamically significant CHD in the Swedish birth cohort born July 1, 2005 to December 31, 2010. Sensitivity (95% confidence interval) of 80% (70–88) for the algorithm was found by analyzing 121 children identified through local hospital data who were treated with palivizumab within a defined region and study period. The positive predictive value was estimated by medical record review in a random sample of 34 cases identified by the algorithm. In 79% (62–91) of these cases, the children were regarded as having hemodynamically significant CHD according to the recommendations for treatment with palivizumab.